Figure 1



Trastuzumab
Trastuzumab MC-resiquimod
Trastuzumab MC-vc-resiquimod
Control IgG
Control no-tranfected cells
% of binding
15
10
5
0
0.01
0.1
1
10
ug/mL

Figure 2



ADCC assay
100
80
60
40
20
0
ADCC%
Trastuzumab
Trastuzumab-MC-TLRL
Trastuzumab-MC-VC-TLRL
hIgG
0
0.001
0.01
0.1
1
10
Antibody Concentration (ug/ml)

Figure 3A



Before enrichment
After enrichment
HLA-DR
Lin
0.8
13
CD11C
CD123
57
32
61
33

Figure 3B



IFNα
TNFα
IL-12
TLRL
Trastuzumab-MC-TLRL
Trastuzumab-MC-vc-TLRL

Figure 3C



IFNα
TNFα
IL-12
TLRL
Trastuzumab-MC-TLRL
Trastuzumab-MC-vc-TLRL
IFN-α (pg/ml)
TNF-α (pg/ml)
IL-12 (pg/ml)

Figure 4A



PBS
Trastuzumab
Trastuzumab MC-vc-resiquimod
Trastuzumab MC-resiquimod
Mean tumor volume (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
Days

Figure 4B




PBS
Trastuzumab
Trastuzumab MC-vc-resiquimod
Trastuzumab MC-resiquimod
Mean Weight, (g, Mean+/-SD)
30
25
20
0
5
10
15
20
25
30
Days

Figure 4C


Percent survival
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
Time
Tramstuzumab-
MC-vc-resiquimod
Transtuzumab
PBS